Arkadios Wealth Advisors Acquires New Shares in Medpace Holdings, Inc. $MEDP

Arkadios Wealth Advisors purchased a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 1,043 shares of the company’s stock, valued at approximately $327,000.

Several other large investors have also bought and sold shares of the stock. Nordea Investment Management AB grew its holdings in Medpace by 4.8% in the second quarter. Nordea Investment Management AB now owns 61,125 shares of the company’s stock worth $19,067,000 after purchasing an additional 2,792 shares during the period. Inspire Investing LLC bought a new position in shares of Medpace during the 1st quarter worth about $2,059,000. Truist Financial Corp boosted its position in shares of Medpace by 10.2% during the 2nd quarter. Truist Financial Corp now owns 12,898 shares of the company’s stock worth $4,048,000 after purchasing an additional 1,197 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Medpace by 10.4% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,182 shares of the company’s stock valued at $371,000 after buying an additional 111 shares during the period. Finally, Voya Investment Management LLC boosted its holdings in Medpace by 7.6% in the first quarter. Voya Investment Management LLC now owns 21,976 shares of the company’s stock worth $6,696,000 after acquiring an additional 1,560 shares in the last quarter. 77.98% of the stock is owned by institutional investors.

Insider Buying and Selling at Medpace

In related news, Director Fred B. Davenport, Jr. sold 5,972 shares of Medpace stock in a transaction on Thursday, October 30th. The shares were sold at an average price of $581.88, for a total value of $3,474,987.36. Following the transaction, the director directly owned 3,498 shares of the company’s stock, valued at $2,035,416.24. The trade was a 63.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, General Counsel Stephen P. Ewald sold 15,230 shares of the company’s stock in a transaction on Monday, October 27th. The shares were sold at an average price of $598.85, for a total transaction of $9,120,485.50. Following the sale, the general counsel owned 13,343 shares of the company’s stock, valued at $7,990,455.55. This represents a 53.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 94,708 shares of company stock worth $50,761,481 over the last quarter. Company insiders own 20.30% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on MEDP shares. Wall Street Zen upgraded shares of Medpace from a “hold” rating to a “buy” rating in a report on Saturday, October 25th. Deutsche Bank Aktiengesellschaft increased their price objective on Medpace from $270.00 to $430.00 and gave the stock a “hold” rating in a research note on Wednesday, July 23rd. Zacks Research raised Medpace from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 27th. UBS Group downgraded Medpace from a “neutral” rating to a “sell” rating and upped their price target for the stock from $300.00 to $305.00 in a report on Tuesday, July 29th. Finally, Truist Financial set a $555.00 price objective on Medpace in a research note on Monday, October 27th. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, nine have given a Hold rating and four have given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $475.90.

Medpace Stock Up 0.7%

Shares of NASDAQ:MEDP opened at $598.81 on Thursday. The stock has a market cap of $16.87 billion, a PE ratio of 41.87, a PEG ratio of 2.67 and a beta of 1.40. The company’s fifty day moving average is $523.07 and its 200 day moving average is $409.00. Medpace Holdings, Inc. has a 52 week low of $250.05 and a 52 week high of $625.00.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.50 by $0.36. The business had revenue of $659.90 million during the quarter, compared to analyst estimates of $640.49 million. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The company’s revenue was up 23.7% on a year-over-year basis. During the same period in the prior year, the business posted $3.01 earnings per share. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. Sell-side analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.